본문 바로가기
KERD
논문KCI 등재

Systematic Review and Meta-Analysis of Damage Associated Molecular Patterns HMGB1 and S100B in Schizophrenia

Michael Mackey|Laurena Holleran|Gary Donohoe|Declan P. McKernan
대한신경정신의학회 (Korean Neuropsychiatric Association)|2022.12|PSYCHIATRY INVESTIGATION|제19권 제12호|pp. 981-990|DOI https://doi.org/10.30773/pi.2022.0173

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

SchizophreniaMeta-analysis.InflammationDanger associated molecular patterns
주제분류정신과학

초록

Objective Immune system dysregulation is hypothesised to be central to the aetiopathogenesis of schizophrenia; however, the role of sterile inflammation remains unclear. Damage associated molecular patterns are key initiators of sterile inflammation and are detectable in peripheral blood. Methods A defined systematic search of the Web of Science, PubMed, and Scopus was performed to identify adult case-control studies published between January 1990 and June 2022. Three studies consisting of 242 cases and 83 controls met inclusion for the systematic review and meta-analysis of HMGB1 while twenty-eight studies consisting of 1,544 cases and 1,248 healthy controls were included for S100B. Results A significant standardised mean difference in peripheral S100B and HMGB1 concentrations was detected between cases and controls. S100B subgroup analysis determined the largest significant effect size for unmedicated individuals diagnosed with schizophrenia. Conclusion This study provides evidence that peripheral S100B and HMGB1 concentrations are elevated in individuals diagnosed with schizophrenia when compared with healthy controls. These results should be interpreted with caution as significant heterogeneity was present during meta-analysis of S100B in the entire sample and in sub-group analysis. The persistence of significant heterogeneity throughout subgroup analysis indicates that the current diagnostic groupings may be a barrier to understanding human behaviours and emotions.

Abstract

Objective Immune system dysregulation is hypothesised to be central to the aetiopathogenesis of schizophrenia; however, the role of sterile inflammation remains unclear. Damage associated molecular patterns are key initiators of sterile inflammation and are detectable in peripheral blood. Methods A defined systematic search of the Web of Science, PubMed, and Scopus was performed to identify adult case-control studies published between January 1990 and June 2022. Three studies consisting of 242 cases and 83 controls met inclusion for the systematic review and meta-analysis of HMGB1 while twenty-eight studies consisting of 1,544 cases and 1,248 healthy controls were included for S100B. Results A significant standardised mean difference in peripheral S100B and HMGB1 concentrations was detected between cases and controls. S100B subgroup analysis determined the largest significant effect size for unmedicated individuals diagnosed with schizophrenia. Conclusion This study provides evidence that peripheral S100B and HMGB1 concentrations are elevated in individuals diagnosed with schizophrenia when compared with healthy controls. These results should be interpreted with caution as significant heterogeneity was present during meta-analysis of S100B in the entire sample and in sub-group analysis. The persistence of significant heterogeneity throughout subgroup analysis indicates that the current diagnostic groupings may be a barrier to understanding human behaviours and emotions.

참고문헌 (98)

  1. McCutcheon RA, "Schizophrenia-an overview", JAMA Psychiatry, 77, pp.201~210 (2020)
  2. World Health Organization, "ICD-10: international statistical classification of diseases and related health problems: 10th revision (2nd ed)", World Health Organization, ~ (2004)
  3. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Association
  4. Cannon TD, "Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk", Biol Psychiatry, 77, pp.147~157 (2015)
  5. Weinhard L, "Microglia remodel synapses by presynaptic trogocytosis and spine head filopodia induction", Nat Commun, 9, pp.1228~ (2018)
  6. Khandaker GM, "Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment", Lancet Psychiatry, 2, pp.258~270 (2015)
  7. van Kesteren CF, "Immune involvement in the pathogenesis of schizophrenia:a meta-analysis on postmortem brain studies", Transl Psychiatry, 7, pp.e1075~ (2017)
  8. Dennison CA, "Genome-wide association studies in schizophrenia: recent advances, challenges and future perspective", Schizophr Res, 217, pp.4~12 (2020)
  9. O’Connell G, "Schizophrenia risk genes: implications for future drug development and discovery", Biochem Pharmacol, 81, pp.1367~1373 (2011)
  10. Barker V, "An integrated biopsychosocial model of childhood maltreatment and psychosis", Br J Psychiatry, 206, pp.177~180 (2015)
  11. Engel GL, "The clinical application of the biopsychosocial model", J Med Philos, 6, pp.101~124 (1981)
  12. Miller BJ, "Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects", Biol Psychiatry, 70, pp.663~671 (2011)
  13. Canetta S, "Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort", Am J Psychiatry, 171, pp.960~968 (2014)
  14. Eaton WW, "Association of schizophrenia and autoimmune diseases: linkage of Danish national registers", Am J Psychiatry, 163, pp.521~528 (2006)
  15. Land W, "Allograft injury mediated by reactive oxygen species: from conserved proteins of Drosophila to acute and chronic rejection of human transplants. Part II: role of reactive oxygen species in the induction of the heat shock response as a regulator of innate", Transplant Rev, 17, pp.31~44 (2003)
  16. Zindel J, "DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation", Annu Rev Pathol, 15, pp.493~518 (2020)
  17. Cochran AJ, "S-100 protein remains a practical marker for melanocytic and other tumours", Melanoma Res, 3, pp.325~330 (1993)
  18. Oris C, "The biomarker S100B and mild traumatic brain injury: a meta-analysis", Pediatrics, 141, pp.e20180037~ (2018)
  19. Rickmann M, "S100 protein expression in subpopulations of neurons of rat brain", Neuroscience, 67, pp.977~991 (1995)
  20. Michetti F, "Immunohistochemical localization of S-100-containing cells in non-nervous structures of the human eye", Cell Biol Int Rep, 10, pp.765~773 (1986)
  21. Li D, "S100B suppresses the differentiation of C3H", 10T1, Mol Med Rep, pp.2016, 14[DOI]
  22. Riuzzi F, "S100B protein regulates myoblast proliferation and differentiation by activating FGFR1 in a bFGF-dependent manner", J Cell Sci, 124(Pt 14), pp.2389~2400 (2011)
  23. Xiong Z, "Enhanced calcium transients in glial cells in neonatal cerebellar cultures derived from S100B null mice", Exp Cell Res, 257, pp.281~289 (2000)
  24. Gógl G, "Structural basis of ribosomal S6 kinase 1 (RSK1) inhibition by S100B protein:modulation of the extracellular signal-regulated kinase (ERK) signaling cascade in a calcium-dependent way", J Biol Chem, 291, pp.11~27 (2016)
  25. Donato R, "Calcium-independent, pH-regulated effects of S-100 proteins on assembly-disassembly of brain microtubule protein in vitro", J Biol Chem, 263, pp.106~110 (1988)
  26. Bianchi R, "S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release", J Biol Chem, 286, pp.7214~7226 (2011)
  27. Businaro R, "S100B protects LAN-5 neuroblastoma cells against Abeta amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Abeta amyloid neurotoxicity at high doses", J Neurosci Res, 83, pp.897~906 (2006)
  28. Andersson U, "Extracellular HMGB1 as a therapeutic target in inflammatory diseases", Expert Opin Ther Targets, 22, pp.263~277 (2018)
  29. Youn JH, "Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion", J Immunol, 177, pp.7889~7897 (2006)
  30. Bonaldi T, "Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion", EMBO J, 22, pp.5551~5560 (2003)
  31. Sha Y, "HMGB1 develops enhanced proinflammatory activity by binding to cytokines", J Immunol, 180, pp.2531~2537 (2008)
  32. Yang M, "HMGB1-induced endothelial cell pyroptosis is involved in systemic inflammatory response syndrome following radiofrequency ablation of hepatic hemangiomas", Am J Transl Res, 11, pp.7555~7567 (2019)
  33. Brezniceanu ML, "HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma", FASEB J, 17, pp.1295~1297 (2003)
  34. Cuijpers P, "Meta-analyses in mental health research. A practical guide", VU University Amsterdam, ~ (2016)
  35. Laird NM, "Random-effects models for longitudinal data", Biometrics, 38, pp.963~974 (1982)
  36. Hedges LV, "Statistical methods for meta-analysis" (1985), Academic Press
  37. Cochran WG, "The combination of estimates from different experiments", Biometrics, 10, pp.101~129 (1954)
  38. Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)
  39. Orwin RG, "A fail-safe N for effect size in meta-analysis", J Educ Stat, 8, pp.157~159 (1983)
  40. Begg CB, "Operating characteristics of a rank correlation test for publication bias", Biometrics, 50, pp.1088~1101 (1994)
  41. Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315, pp.629~634 (1997)
  42. Duval S, "A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis", J Am Stat Assoc, 95, pp.89~98 (2000)
  43. Şahin M, "Jamovi: an easy to use statistical software for the social scientists", Int J Assess Tool Educ, 6, pp.670~692 (2019)
  44. Page MJ, "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews", BMJ, 372, pp.n71~ (2021)
  45. Kozłowska E, "Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia", J Psychiatr Res, 138, pp.380~387 (2021)
  46. Mousa RF, "Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates", Metab Brain Dis, 36, pp.169~183 (2021)
  47. Yilmaz N, "High mobility group box-1 levels in schizophrenia: potential biomarker of remission phase", J Med Biochem, 40, pp.295~301 (2021)
  48. Overall JE, "The Brief Psychiatric Rating Scale (BPRS):recent developments in ascertainment and scaling", Psychopharmacol Bull, 24, pp.97~99 (1988)
  49. Andreasen NC, "Scale for the assessment of positive symptoms (SAPS)", University of Iowa, ~ (1984)
  50. Iager AC, "A negative symptom rating scale", Psychiatry Res, 16, pp.27~36 (1985)
  51. Aleksovska K, "Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia", PLoS One, 9, pp.e106342~ (2014)
  52. Schroeter ML, "Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia--original research and meta-analysis", Psychiatry Res, 167, pp.66~72 (2009)
  53. Steiner J, "Haloperidol and clozapine decrease S100B release from glial cells", Neuroscience, 167, pp.1025~1031 (2010)
  54. Capuzzi E, "Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: a meta-analysis", Neurosci Biobehav Rev, 77, pp.122~128 (2017)
  55. Song XQ, "The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia", Biol Psychiatry, 65, pp.481~488 (2009)
  56. Romeo B, "Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: a meta-analysis", Int J Neuropsychopharmacol, 21, pp.828~836 (2018)
  57. Song X, "Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia", Psychopharmacology (Berl), 231, pp.319~325 (2014)
  58. Tourjman V, "Antipsychotics’ effects on blood levels of cytokines in schizophrenia: a meta-analysis", Schizophr Res, 151, pp.43~47 (2013)
  59. Zhang XY, "Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia", J Clin Psychiatry, 65, pp.940~947 (2004)
  60. Kang R, "HMGB1 in health and disease", Mol Aspects Med, 40, pp.1~116 (2014)
  61. Rothermundt M, "S100B in brain damage and neurodegeneration", Microsc Res Tech, 60, pp.614~632 (2003)
  62. Tzoulaki I, "Size at birth, weight gain over the life course, and lowgrade inflammation in young adulthood: northern Finland 1966 Birth Cohort study", Eur Heart J, 29, pp.1049~1056 (2008)
  63. Nettleton JA, "Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA)", Am J Clin Nutr, 83, pp.1369~1379 (2006)
  64. Lee J, "Cigarette smoking and inflammation: cellular and molecular mechanisms", J Dent Res, 91, pp.142~149 (2012)
  65. Starkie R, "Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans", FASEB J, 17, pp.884~886 (2003)
  66. Allsopp K, "Heterogeneity in psychiatric diagnostic classification", Psychiatry Res, 279, pp.15~22 (2019)
  67. Wardenaar KJ, "Diagnostic heterogeneity in psychiatry: towards an empirical solution", BMC Med, 11, pp.201~ (2013)
  68. Khandaker GM, "Association between circulating levels of C-reactive protein and positive and negative symptoms of psychosis in adolescents in a general population birth cohort", J Psychiatr Res, 143, pp.534~542 (2021)
  69. Cuthbert BN, "The RDoC framework: facilitating transition from ICD", DSM to dimensional approaches that integrate neuroscience and psychopathology, 2014, pp.13, 28~35
  70. Saha S, "A systematic review of mortality in schizophrenia:is the differential mortality gap worsening over time?", Arch Gen Psychiatry, 64, pp.1123~1131 (2007)
  71. Murray CJ, "Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study", Lancet, 349, pp.1436~1442 (1997)
  72. Moher D, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement", BMJ, 339, pp.b2535~ (2009)
  73. Chen S, "Cognitive dysfunction correlates with elevated serum S100B concentration in drugfree acutely relapsed patients with schizophrenia", Psychiatry Res, 247, pp.6~11 (2017)
  74. Dai N, "Different serum protein factor levels in first-episode drug-naive patients with schizophrenia characterized by positive and negative symptoms", Psychiatry Clin Neurosci, 74, pp.472~479 (2020)
  75. Hendouei N, "Negative correlation between serum S100B and leptin levels in schizophrenic patients during treatment with clozapine and risperidone: preliminary evidence", Iran J Pharm Res, 15, pp.323~330 (2016)
  76. Hong W, "Higher plasma S100B concentrations in schizophrenia patients, and dependently associated with inflammatory markers", Sci Rep, 6, pp.27584~ (2016)
  77. Lara DR, "Increased serum S100B protein in schizophrenia : a study in medication-free patients", J Psychiatr Res, 35, pp.11~14 (2001)
  78. Ling SH, "Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment", J Psychiatr Res, 41, pp.36~42 (2007)
  79. Milleit B, "Serum S100B protein is specifically related to white matter changes in schizophrenia", Front Cell Neurosci, 10, pp.33~ (2016)
  80. Morera-Fumero AL, "Day", night changes in serum S100B protein concentrations in acute paranoid schizophrenia, 2017, pp.75, 207~212
  81. Qi LY, "Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics", Neurosci Lett, 462, pp.113~117 (2009)
  82. Rothermundt M, "Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology", Mol Psychiatry, 6, pp.445~449 (2001)
  83. Rothermundt M, "S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia", Neuropsychopharmacology, 29, pp.1004~1011 (2004)
  84. Rothermundt M, "Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF", Mol Psychiatry, 9, pp.897~899 (2004)
  85. Rothermundt M, "Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.361~364 (2007)
  86. Kim HR, "Increased serum S100B protein in chronic schizophrenic patients in Korea", Clin Chem Lab Med, 45, pp.1561~1563 (2007)
  87. Šakić M, "Increased calcium-independent lipoprotein phospholipase A2 but not protein S100 in patients with schizophrenia", Psychiatr Danub, 28, pp.45~50 (2016)
  88. Sarandol A, "Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia : effects of short term antipsychotic treatment", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1164~1169 (2007)
  89. Schmitt A, "Increased serum S100B in elderly, chronic schizophrenic patients : negative correlation with deficit symptoms", Schizophr Res, 80, pp.305~313 (2005)
  90. Schroeter ML, "Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia", Schizophr Res, 62, pp.231~236 (2003)
  91. Steiner J, "Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones", J Neurol Neurosurg Psychiatry, 77, pp.1284~1287 (2006)
  92. Steiner J, "S100B serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance", Cardiovasc Psychiatry Neurol, 2010, pp.480707~ (2010)
  93. Uzbay T, "Increased plasma agmatine levels in patients with schizophrenia", J Psychiatr Res, 47, pp.1054~1060 (2013)
  94. Wiesmann M, "Elevated plasma levels of S-100b protein in schizophrenic patients", Biol Psychiatry, 45, pp.1508~1511 (1999)
  95. Xiong P, "Combining serum protein concentrations to diagnose schizophrenia: a preliminary exploration", J Clin Psychiatry, 75, pp.e794~e801 (2014)
  96. Zhang XY, "Increased serum S100B in never-medicated and medicated schizophrenic patients", J Psychiatr Res, 44, pp.1236~1240 (2010)
  97. Gattaz WF, "Decreased S100-beta protein in schizophrenia: preliminary evidence", Schizophr Res, 43, pp.91~95 (2000)
  98. O’Connell K, "Levels of S100B are raised in female patients with schizophrenia", BMC Psychiatry, 13, pp.146~ (2013)

관련 논문AI추천

Erratum : Systematic Review and Meta-Analysis of Damage Associated Molecular Patterns HMGB1 and S100B in SchizophreniaDeclan P. McKernan, Gary Donohoe, Laurena Holleran, Michael Mackey대한신경정신의학회 · PSYCHIATRY INVESTIGATION2024 · 제21권 제1호Peripheral Biomarkers for First-Episode Psychosis—Opportunities from the Neuroinflammatory Hypothesis of SchizophreniaJoana Prata, Mário Barbosa, Nuno Trovão, Orlando VonDoellinger, Rui Coelho, Susana Santos대한신경정신의학회 · PSYCHIATRY INVESTIGATION2019 · 제16권 제3호The Neuroimmunology of SchizophreniaAnnya M. Smyth, Stephen M. Lawrie대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2013 · 제11권 제3호Distinct Inflammation Biomarkers in Healthy Individuals and Patients with Schizophrenia: A Reliability Testing of Multiplex Cytokine Immunoassay by Bland-Altman AnalysisChia-Kuang Tsai, Chih-Sung Liang, Fu-Chi Yang, Hsin-An Chang, Hsuan-Te Chu, San-Yuan Huang, Ta-Chuan Yeh대한신경정신의학회 · PSYCHIATRY INVESTIGATION2019 · 제16권 제8호Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug RepurposingJonghee Hong, Minji Bang대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2020 · 제18권 제1호C-Reactive Protein/Albumin and Neutrophil/Albumin Ratios as Novel Inflammatory Markers in Patients with SchizophreniaBalcioglu Yasin Hasan, Kirlioglu Simge Seren대한신경정신의학회 · PSYCHIATRY INVESTIGATION2020 · 제17권 제9호

이 간행물의 다른 논문 (9건)

Deconstructing Mechanisms of Abnormal Categorical Perception of Emotional Facial Expressions in Schizophrenia PatientsJian Zhang, Yunzhen Xue, Ruomin Wangpp. 991-999Efficacy of Mobile-Based Cognitive Training Program DoBrain in Preschool Children With or Without Developmental Disabilities: A Randomized, Single-Blind, Active-Controlled Trial김효원, Seonok Kim, Kee Jeong Park, Jichul Kim, Taeyeop Leepp. 1000-1011Parental Psychological Aggression and Phubbing in Adolescents: A Moderated Mediation ModelHua Cao, Tingting Gao, Songli Mei, Xiangfei Meng, Chengchao Zhou, Leilei Liangpp. 1012-1020Psychometric Properties of the Mental Health Continuum-Short Form (MHC-SF): A Study With Individuals With Schizophrenia Living in the Community임영진pp. 1021-1026The Effect of TNF-alpha rs1800629 Polymorphism on White Matter Structures and Memory Function in Patients With Schizophrenia: A Pilot StudyWonsuk Shin, Sra Jung, 이상혁, 방민지, Naok Kangpp. 1027-1036
원문 보기